Treatment Patterns, Effectiveness, and Safety of Originator Insulin Glargine versus Insulin Glargine-yfgn within the Veterans Health Administration

Treatment Patterns, Effectiveness, and Safety of Originator Insulin Glargine versus Insulin Glargine-yfgn within the Veterans Health Administration

We described insulin glargine (originator) and insulin glargine-yfgn (biosimilar) treatment patterns, assessed effectiveness and safety outcomes, and identified reasons for switching back to the originator product from the biosimilar. This retrospective study included 328,463 Veterans 18 years of ag...

Full description

Bibliographic Details
Main Authors: Samantha Walczuk, Francesca E. Cunningham, Xinhua Zhao, Diane Dong, Peter A. Glassman, Donald R. Miller, Deborah Khachikian, Anthony Au, Cedric Salone, Kelly Bryan, Qoua Her, Sherrie L. Aspinall
Format: Article
Language:English
Published: MDPI AG 2024-03-01
Series:Pharmacoepidemiology
Subjects:
insulin glargine
biosimilar pharmaceuticals
drug safety
Online Access:https://www.mdpi.com/2813-0618/3/1/8

Internet

https://www.mdpi.com/2813-0618/3/1/8

Similar Items